

Lepu Medical Technology (Beijing) Co., Ltd.

The First Quarter Report in 2025

The Company and all members of the Board of Directors warrant that the information disclosed is authentic, accurate and complete, and contains no false records, misleading statements or material omissions.

Hint of Important Contents:

1. The Board of Directors, the Board of Supervisors, directors, supervisors, and senior executives of the Company shall guarantee the truthfulness, accuracy and completeness of the content of the quarterly report, without any false records, misleading statements or material omissions, and also assume several and joint legal liabilities.
2. The head of the Company, person in charge of accounting and person in charge of accounting department (accounting supervisor) hereby declare that: the financial information disclosed in the quarterly report is true, accurate and complete.
3. Whether the Q1 Report has passed the audit
Yes No

I. Key Financial Data

(I) Major accounting data and financial indexes

Whether the Company needs to retrospectively adjust or restate previous annual accounting data?

Yes No

	Current reporting period	Same period of last year	The increase/decrease of the report period from the same period of the previous year (%)
Operating income (RMB)	1, 736, 231, 253. 08	1, 922, 028, 839. 15	-9. 67%
Net profits attributable to shareholders of the listed companies (RMB)	378, 539, 846. 83	481, 871, 134. 58	-21. 44%
Net profits attributable to shareholders of the listed company after deducting non-recurring profits and losses (RMB)	337, 386, 464. 42	456, 433, 815. 92	-26. 08%
Net cash flow from operating activities (RMB)	419, 022, 240. 55	141, 518, 257. 63	196. 09%
Basic earnings per share (RMB/share)	0. 2053	0. 2594	-20. 86%
Diluted earnings per share (RMB/share)	0. 2053	0. 2585	-20. 58%
Weighted average return on net assets	2. 46%	2. 98%	-0. 52%

	End of current reporting period	End of the last year	The increase/decrease of the report period from the end of the previous year (%)
Total assets (RMB)	25,233,363,806.46	24,573,100,199.19	2.69%
Owners' equities attributable to shareholders of the Company (RMB)	15,615,828,015.50	15,201,421,378.82	2.73%

From the end of the reporting period to the disclosure date of the quarterly report, whether the share capital of the Company has changed due to the issuance of new shares, additional issuance, allotment, equity incentive exercise, repurchase and other reasons and whether the share capital of the Company has affected the amount of owners' equity.

Yes No

	Current reporting period
Paid preferred stock dividend (RMB)	0.00
Paid interest of perpetual bonds (RMB)	0.00
Fully diluted earnings per share calculated in accordance with the latest capital stock (RMB/share)	0.2013

(II) Items and amounts of non-recurring profits or losses

Applicable Not applicable

Unit: RMB

Item	Amount in the current reporting period	Instruction
Profits and losses on disposal of non-current assets (including the write-off of provision for asset impairment)	-708,663.30	
Government subsidies included in current profits and losses (except for government subsidies closely related to the normal business operations of Company, in line with national policies and obtained according to established standards and having continuous influence on the profits and losses of the Company)	48,570,775.38	
Profit or loss on changes in fair values of held-for-trading financial assets and financial liabilities by non-financial enterprises and profit or loss obtained from disposal of financial assets and financial liabilities, except for effective hedging operations associated with the Company's normal operation	424,316.92	
Non-operating income and expenditure other than those mentioned above	-2,979,938.22	
Other items of profits and losses that meet the definition of non-recurring profits and losses	-1,235,762.45	
Minus: Influenced amount of income tax	2,019,643.46	
Influenced amount of minority shareholders' equities (after-tax)	897,702.46	
Total	41,153,382.41	--

Details of other profit and loss items complying with the definition of non-recurring profits or losses

Applicable Not applicable

The Company has no details of other profit and loss items complying with the definition of non-recurring profits or losses

Description on situations for defining non-recurring profit and loss items listed in the *Explanatory Announcement No.1 on Disclosure of the Information of Companies Offering Their Securities to the Public - Non-recurring Profits and Losses* as recurring profits and losses.

Applicable Not applicable

The Company has no situations for defining non-recurring profit and loss items listed in the *Explanatory Announcement No.1 on Disclosure of the Information of Companies Offering Their Securities to the Public - Non-recurring Profits and Losses* as recurring profits and losses.

(III) Details and reasons of changes of major accounting data and financial indexes

Applicable Not applicable

1. During the reporting period, the company's operating revenue was RMB 1,736.2313 million, a decrease of RMB 185.7976 million year-on-year, down 9.67%. Revenue entered a stable growth trajectory quarter-on-quarter, increasing by RMB 418.4338 million compared to Q4 2024, up 31.75%.

1) The medical device segment, the largest contributor to operating revenue, generated RMB 903.7488 million during the reporting period, up 2.05% year-on-year.

The cardiovascular intervention business achieved operating revenue of RMB 619.0155 million, a year-on-year increase of 8.49%. Among them, coronary intervention business achieved operating revenue of RMB 446.8958 million, with a year-on-year increase of 2.03%. Structural heart disease business achieved operating revenue of RMB 154.9288 million, with a year-on-year increase of 37.44%.

Surgical anesthesia business: The operating income reached RMB 140.1516 million, with a year-on-year increase of 2.53%.

In vitro diagnosis business: The operating income reached RMB 88.4425 million, with a year-on-year decrease of 19.87%.

2) The pharmaceutical segment achieved RMB 594.7917 million, up 111.38% quarter-on-quarter, with retail channel inventory clearance largely completed, the proportion of atorvastatin calcium and clopidogrel bisulfate in the revenue structure has been gradually decreasing. The operating income of active pharmaceutical ingredients reached RMB 83.1147 million, with a quarter-on-quarter increase of 29.35%; The operating income of preparations reached RMB 511.677 million, with a quarter-on-quarter decrease of 135.65%.

3) The medical services and health management segment generated RMB 237.6908 million during the reporting period.

2. Due to centralized procurement and policies of "price regulation of four sameness drugs", the gross margin declined by 2.86 percentage points. However, the company's earlier workforce optimization and organizational restructuring began to yield results, reducing both sales and administrative expenses in absolute terms. During the reporting period, the company achieved a net profit of approximately RMB 377.214 million, a year-on-year decrease of 23.45%; achieved a net profit attributable to shareholders of the listed company of RMB 378.5389 million, a year-on-year decrease of 21.44%; and achieved a net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of RMB 337.3865 million, a year-on-year decrease of 26.08%. During the reporting period, the non-recurring income attributable to shareholders of the listed company was RMB 41.1533 million, compared with a non-recurring

income of RMB 25.4373 million in the same period of the previous year, mainly due to the increase in government R&D support received by the company during the reporting period.

3. During the reporting period, the company's financial expenses were RMB 33.2823 million, an increase of RMB 32.4124 million year-on-year, an increase rate of 3,726.23%, mainly due to the company's exchange loss of RMB 9.2763 million during the reporting period, which was an increase in exchange loss compared with the exchange gain of RMB 13.0605 million in the same period of the previous year.

4. During the reporting period, the company's other income was RMB 52.2650 million, an increase of RMB 30.7457 million year-on-year, an increase rate of 142.88%, mainly due to the increase in government R&D support received by the company related to its daily activities during the reporting period.

5. During the reporting period, the company's investment income was RMB 19.6490 million, an increase of RMB 23.9416 million in income compared with the loss of RMB 4.2926 million in the same period of the previous year, an increase rate of 557.74%, mainly due to the increase in the income of the company's equity-accounted investees confirmed by the company in proportion during the reporting period.

6. During the reporting period, the company's credit impairment loss was RMB 16.1524 million, a decrease of RMB 19.7798 million in income compared with the income of RMB 3.6273 million in the same period of the previous year, a decrease rate of 545.30%, mainly due to the increase in the bad debt provisions for accounts receivable accrued by the company during the reporting period.

7. During the reporting period, the net cash inflow from the company's operating activities was RMB 419.0222 million, an increase of RMB 277.5040 million compared with the same period of the previous year, an increase rate of 196.09%, mainly because the optimization and reset of personnel and the reshaping of the organizational structure have shown initial results during the reporting period, and various expenditures have been reduced to varying degrees while increasing revenue sources.

8. During the reporting period, the net cash outflow from the company's investment activities was RMB 464.0474 million, an increase of RMB 184.0305 million in net outflow compared with the same period of the previous year, an increase rate of 65.72%, mainly due to the company's deposit of a large-denomination certificate of deposit of RMB 260.0000 million during the reporting period, and there was no such event in the same period.

9. During the reporting period, the net cash inflow from the company's financing activities was RMB 82.1628 million, an increase of RMB 134.2249 million in net inflow compared with the net outflow of RMB 52.0621 million in the same period of the previous year, an increase rate of 257.82%, mainly because the expenditure on the acquisition of minority shareholders' equity during the reporting period decreased by RMB 83.0603 million year-on-year. In addition, RMB 70.7418 million was paid for the repurchase of treasury shares in the same period, and there was no such expenditure item in the current period.

10. At the end of the reporting period, the company's trading financial assets were RMB 359.5487 million, an increase of RMB 84.6858 million compared with the beginning of the year, an increase rate of 30.81%, mainly due to the company's new wealth management products during the reporting period.

11. During the reporting period, the company's non-current assets due within one year were RMB 212.4013 million, an increase of RMB 179.3912 million compared with the beginning of the year, an increase rate of 543.44%, mainly because some of the company's large-denomination certificates of deposit matured within one year during the reporting period.

12. At the end of the reporting period, the company's accrued employee compensation was RMB 46.9315 million, a decrease of RMB 38.6166 million compared with the beginning of the year, a decrease rate of 45.14%, mainly because the company paid the bonuses accrued in the previous year during the reporting period.

13. At the end of the reporting period, the company's taxes payable were RMB 187.6542 million, an increase of RMB 51.9989 million compared with the beginning of the year, an increase rate of 38.33%, mainly due to the increase in relevant taxes and fees corresponding to the sequential growth of the company's business during the reporting period.

14. At the end of the reporting period, the company's non-current liabilities due within one year were RMB 2,841.4450 million, an increase of RMB 1,249.7477 million compared with the beginning of the year, an increase rate of 78.52%, mainly because the company's convertible bonds will mature within one year during the reporting period.

15. At the end of the reporting period, the company's other comprehensive loss was 24.5844 million yuan. Compared with the loss of 41.3478 million yuan at the beginning of the year, the income increased by 16.7634 million yuan, representing an increase rate of 40.54%. This was mainly due to the increase in the fair value of other equity instrument investments held by the company during the reporting period.

II. Information of Shareholders

(I) Table of Total Number of Common Shareholders and Preferred Shareholders Recovering Voting Rights and Shareholdings of Top Ten Shareholders

Unit: Share

Total number of common shareholders at the end of the reporting period		94,228	Total number of preferred shareholders recovering voting rights at the end of reporting period (if any)		0	
Shareholding status of the top ten shareholders (excluding shares lent through transfer financing business)						
Name of shareholder(s)	Nature of shareholder(s)	Shareholding proportion (%)	Number of shares held	Number of shares held with restricted conditions	Pledge, marking or freezing information	
					Share status	Quantity
Luoyang Ship Material Research Institute	State-owned legal person	12.98%	244,063,788	0.00	N/A	
PU Zhongjie	Domestic natural person	12.13%	228,074,749	171,056,062	Pledge	155,809,988
WP MEDICAL TECHNOLOGIES, INC	Foreign legal person	6.59%	123,968,600	92,976,450	Pledge	85,000,000
Houde Yimin (Beijing) Investment Management Co., Ltd.	Domestic non-state-owned legal person	3.60%	67,750,000	0	N/A	

Bank of China Limited - Huabao CSI Medical ETF	Others	2.29%	43,019,418	0	N/A	
Houde Yimin (Ningbo) Investment Management Co., Ltd.	Domestic non-state-owned legal person	1.91%	35,850,000	0	N/A	
Industrial and Commercial Bank of China Limited - E Fund ChiNext ETF	Others	1.66%	31,289,277	0	N/A	
Agricultural Bank of China Limited - CSI 500 ETF	Others	0.90%	17,016,340	0	N/A	
Hong Kong Securities Clearing Company Limited	Foreign legal person	0.81%	15,153,580	0	N/A	
China Construction Bank Limited - Huan ChiNext 50 ETF	Others	0.66%	12,494,114	0	N/A	
Shareholding of the top 10 shareholders with non-restricted conditions						
Name of shareholder(s)	Number of shares held without restricted conditions	Type of shares				
		Type of shares	Quantity			
Luoyang Ship Material Research Institute	244,063,788	A share	244,063,788			
Houde Yimin (Beijing) Investment Management Co., Ltd.	67,750,000	A share	67,750,000			
PU Zhongjie	57,018,687	A share	57,018,687			
Bank of China Limited - Huabao CSI Medical ETF	43,019,418	A share	43,019,418			
Houde Yimin (Ningbo) Investment Management Co., Ltd.	35,850,000	A share	35,850,000			
Industrial and Commercial Bank of China Limited - E Fund ChiNext ETF	31,289,277	A share	31,289,277			
WP MEDICAL TECHNOLOGIES, INC	30,992,150	A share	30,992,150			
Agricultural Bank of China Limited - CSI 500 ETF	17,016,340	A share	17,016,340			
Hong Kong Securities Clearing Company Limited	15,153,5800	A share	15,153,580			
China Construction Bank Limited - Huan ChiNext 50 ETF	12,494,114	A share	12,494,114			
Description of associated relationships or concerted actions of the above shareholders	Mr. PU Zhongjie, WP Medical Technologies, Inc., Houde Yimin (Beijing) Investment Management Co., Ltd. and Houde Yimin (Ningbo) Investment Management Co., Ltd. were persons acting in concert within the meaning of PRC law. There was no relationship between other shareholders of the Company or concerted action as stipulated in					

	Measures for the Administration of Acquisition of Listed Companies (Order No.35 of China Securities Regulatory Commission).
Description of the top 10 shareholders participating in financing and securities business (if any)	None

Shareholders holding more than 5% of shares, the top 10 shareholders and the top 10 shareholders with unrestricted shares participating in the refinancing business to lend shares

Applicable Not applicable

Top 10 shareholders and the top 10 shareholders with unrestricted shares changed from the previous period due to lending/returning of refinancing

Applicable Not applicable

(II) Table of Total Number of the Preferred Shareholders and Shareholdings of Top 10 Preferred Shareholders of the Company

Applicable Not applicable

(III) Statement of restricted share change

Applicable Not applicable

Unit: Share

Name of shareholder(s)	Quantity of restricted stocks at the beginning of the period	Quantity of stocks removed with restrictions on sales in current period	Quantity of stocks increased with restrictions on sales in current period	Quantity of restricted stocks at the end of the period	Reason for restriction on sales	Date of cancellation of the restriction
PU Zhongjie	171,056,062			171,056,062	Restricted circulation stock held by senior executives	During Mr. PU Zhongjie's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
WP MEDICAL TECHNOLOGIES, INC	92,976,450			92,976,450	Pre-sale restricted shares	During Mr. PU Zhongjie's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the

						Company, and he will not transfer the shares of the Company within half a year after his resignation.
WEI Zhanjiang	145,200			145,200	Restricted circulation stock held by senior executives	During Mr. ZHANG Zhibin's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
WANG Yong	143,775			143,775.00	Restricted circulation stock held by senior executives	During Ms. WANG Yong's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and she will not transfer the shares of the Company within half a year after his resignation.
FENG Xiaoying	5,550			5,550	Restricted circulation stock held by senior executives	During Ms. FENG Xiaoying's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and she will not

						transfer the shares of the Company within half a year after his resignation.
ZHANG zhibin	217, 500	54, 375		163, 125	Restricted circulation stock held by senior executives	During Mr. ZHANG Zhibin's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
ZHENG Guorui	30, 000	7, 500		22, 500	Restricted circulation stock held by senior executives	During Mr. ZHENG Guorui's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Total	264, 574, 537	61, 875	0	264, 512, 662		

III. Other Major Events

Applicable Not applicable

The Company convened the 13th Meeting of the 6th Board of Directors on February 25, 2025, which reviewed and approved the "Proposal on Not Making Downward Adjustment to the Conversion Price of 'Lepu Convertible Bond 2'". The Board resolved not to downward adjust the conversion price this time, and further determined that even if the downward adjustment clause is

triggered again within the next six months (from February 26, 2025 to August 25, 2025), no downward adjustment proposal will be submitted.

IV. Quarterly Financial Statements

(I) Financial statements

1. consolidated balance sheet

Prepared by: Lepu Medical Technology (Beijing) Co., Ltd.

2025/3/31

Unit: RMB

Item	Ending balance	Beginning balance
Current assets:		
Monetary capital	3,729,685,667.04	3,718,016,911.13
Deposit reservation for balance		
Lending funds		
Trading financial assets	359,548,701.91	274,862,862.96
Derivative financial assets		
Notes receivable	101,799,300.04	116,747,820.08
Accounts receivable	1,857,183,008.74	1,530,657,231.48
Receivables financing	125,879,359.27	159,509,608.70
Advance payment	274,317,299.30	226,737,694.48
Premium receivable		
Reinsurance accounts receivable		
Reserves for reinsurance contract receivable		
Other receivables	115,331,369.16	114,401,883.63
Including: Interests receivable		
Dividends receivable		
Redemptory monetary capital for sale		
Inventory	1,977,616,736.79	2,030,235,942.18
Including: Data resource		
Contract assets		
Held-for-sale assets		
Non-current assets due within one year	212,401,339.18	33,010,145.09
Other current assets	253,053,966.18	232,101,603.89
Total current assets	9,006,816,747.61	8,436,281,703.62
Non-current assets:		
Loan granted and advances		
Creditor's right investments		
Other creditor's right investments		
Long-term receivables		189,453.63
Long-term equity investments	1,212,784,329.49	1,189,771,189.43
Other equity instrument investments	1,079,299,413.04	1,086,887,464.61
Other non-current financial assets	26,500,000.00	26,500,000.00
Investment property	467,925,335.33	463,953,038.77
Fixed assets	3,908,799,918.10	3,991,276,420.92
Engineering in progress	584,448,146.14	533,097,328.96
Productive biological assets		
Oil-gas assets		
Right-of-use assets	326,610,321.75	338,472,348.46
Intangible assets	2,007,878,697.48	2,018,616,893.91

Including: Data resource		
Development expenditures	1,036,658,214.62	1,020,885,502.67
Including: Data resource		
Goodwill	3,619,848,802.32	3,619,848,802.32
Long-term unamortized expenses	288,924,196.62	290,734,919.11
Deferred income tax assets	308,570,163.35	314,866,760.31
Other non-current assets	1,358,299,520.61	1,241,718,372.47
Total non-current assets	16,226,547,058.85	16,136,818,495.57
Total assets	25,233,363,806.46	24,573,100,199.19
Current liabilities:		
Short-term borrowings	287,470,323.14	301,656,435.95
Borrowings from the central bank		
Borrowing funds		
Trading financial liabilities	196,887.09	93,983.38
Derivative financial liabilities		
Notes payable	81,611,740.21	87,698,748.88
Accounts payable	760,839,113.77	709,454,994.52
Advance receipt		
Contract liabilities	248,092,460.24	242,043,458.27
Financial assets sold for repurchase		
Deposits from customers and interbank		
Acting trading securities		
Acting underwriting securities		
Employee remuneration payable	46,931,532.68	85,548,165.19
Taxes payable	187,654,171.33	135,655,297.65
Other payables	443,435,003.43	397,963,800.74
Including: Interests payable		
Dividends payable	2,649,356.31	3,071,231.31
Fees and commissions payable		
Reinsurance accounts payable		
Held-for-sale liabilities		
Non-current abilities due within one year	2,841,444,978.84	1,591,697,242.05
Other non-current liabilities	58,740,146.66	60,739,818.02
Total non-current liabilities	4,956,416,357.39	3,612,551,944.65
Non-current liabilities:		
Reserves for insurance contract		
Long-term borrowings	2,521,979,011.72	2,015,583,172.32
Bonds payables		1,608,915,230.87
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	250,426,167.18	251,912,745.16
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred incomes	141,625,048.15	137,907,778.27
Deferred income tax liabilities	203,689,282.55	205,793,013.00
Other current liabilities		
Total current liabilities	3,117,719,509.60	4,220,111,939.62
Total liabilities	8,074,135,866.99	7,832,663,884.27
Owners' equities:		
Share capital	1,880,611,082.00	1,880,611,005.00
Other equity instruments	214,746,865.47	214,747,153.96
Including: Preferred shares		

Perpetual bonds		
Capital reserves	3,554,749,412.41	3,533,592,427.30
Minus: Treasury shares	608,492,292.32	608,492,292.32
Other comprehensive incomes	-24,584,399.43	-41,347,794.62
Special reserves		
Surplus reserves	787,909,316.71	787,909,316.71
General risk reserves		
Undistributed profits	9,810,888,030.66	9,434,401,562.79
Total owners' equities attributable to the parent company	15,615,828,015.50	15,201,421,378.82
Minority equity	1,543,399,923.97	1,539,014,936.10
Total owners' equities	17,159,227,939.47	16,740,436,314.92
Total liabilities and owner's equities	25,233,363,806.46	24,573,100,199.19

Legal representative: Pu Zhongjie Chief Financial Officer: Wang Yong Accounting Manager: Li Yun

2. Consolidated Profit Statement

Unit: RMB

Item	Accrual in the current period	Accrual in the last period
I. Total operating income	1,736,231,253.08	1,922,028,839.15
Including: Operating incomes	1,736,231,253.08	1,922,028,839.15
Interest incomes		
Earned premium		
Incomes from fees and commissions		
II. Total operating costs	1,321,825,918.33	1,336,348,890.00
Including: Operating cost	624,607,361.27	636,463,766.47
Interest expenditure		
Expenditures from fees and commissions		
Surrender value		
Net amount of compensation payout		
Withdrawal of net amount of reserve fund for insurance liabilities		
Bond insurance expense		
Reinsurance expenses		
Taxes and surcharges	23,165,185.55	24,345,130.02
Sales expense	298,470,737.67	334,350,310.50
Management expense	138,974,325.21	142,934,575.75
R&D expenses	203,326,022.08	197,385,261.91
Financial expense	33,282,286.55	869,845.35
Including: Interest expenses	44,734,185.01	42,207,977.95
Interest incomes	21,802,480.09	29,411,929.40
Plus: Other incomes	52,264,969.51	21,519,244.45
Return on investment (the loss is expressed with "-")	19,648,975.20	-4,292,647.74
Including: Return on investment in associated enterprises and joint ventures	19,655,510.14	-15,814,845.75

Income from derecognition of financial assets measured at amortized cost		
Foreign exchange gains (the loss is expressed with "-")		
Income from net exposure hedging (the loss is expressed with "-")		
Income from change in fair value (the loss is expressed with "-")	937,293.80	3,416,117.92
Credit impairment loss (the loss is expressed with "-")	-16,152,446.12	3,627,336.50
Asset impairment loss (the loss is expressed with "-")	-2,271,438.27	-328,202.44
Income from asset disposal (the loss is expressed with "-")	-385,049.34	-400,599.42
III. Operating profit (the loss is expressed with "-")	468,447,639.53	609,221,198.42
Plus: Non-operating incomes	2,095,149.76	7,129,312.85
Minus: Non-operating expenditures	5,637,635.19	9,139,008.43
IV. Total profits (the total losses are expressed with "-")	464,905,154.10	607,211,502.84
Minus: Income tax expense	87,691,140.81	114,450,959.38
V. Net profit (the loss is expressed with "-")	377,214,013.29	492,760,543.46
(I) Classified by operation continuity		
1. Net profit from continuing operation (the net loss is expressed in with "-")	377,214,013.29	492,760,543.46
2. Net profit from discontinuing operation (the net loss is expressed in with "-")		
(II) Classification by ownership		
1. Net profits attributable to the owners of the parent company	378,539,846.83	481,871,134.58
2. Minority shareholders' profit and loss	-1,325,833.54	10,889,408.88
VI. After-tax net amount of other comprehensive incomes	11,828,838.14	-8,798,240.24
After-tax net amount of other comprehensive incomes attributable to the owners of the parent company	14,710,016.23	-2,883,682.58
(I) Other comprehensive incomes that cannot be reclassified into profits and losses	7,686,755.72	13,164,998.13
1. Re-measurement of changed amount in the defined benefit plan		
2. Other comprehensive incomes that cannot be transferred into the profits and losses under the equity method		
3. Changes in fair value of other equity instrument investments	7,686,755.72	13,164,998.13
4. Changes in fair value of enterprise credit risk		
5. Others		
(II) Other comprehensive incomes that can be reclassified into profits and	7,023,260.51	-16,048,680.71

losses		
1. Other comprehensive incomes that can be transferred into the profits and losses under the equity method	-16,948.76	-9,038.71
2. Changes in fair value of other creditor's right investments		
3. Amounts of financial assets reclassified into other comprehensive incomes		
4. Credit impairment reserves of other creditor's right investments		
5. Cash flow hedging reserves		
6. Translation difference of foreign currency financial statements	7,040,209.27	-16,039,642.00
7. Others		
After-tax net amount of other comprehensive incomes attributable to the minority shareholders	-2,881,178.09	-5,914,557.66
VII. Total comprehensive incomes	389,042,851.43	483,962,303.22
Total comprehensive incomes attributable to the owners of the parent company	393,249,863.06	478,987,452.00
Total comprehensive incomes attributable to minority shareholders	-4,207,011.63	4,974,851.22
VIII. Earnings per share:		
(I) Basic earnings per share	0.2053	0.2594
(II) Diluted earnings per share	0.2053	0.2585

As for the business combination under the same control in the current period, net profits achieved by the combined party before the combination was:0.00 RMB , and the net profit achieved by the combined party for the last period is:0.00 RMB

Legal representative: Pu Zhongjie Chief Financial Officer: Wang Yong Accounting Manager: Li Yun

3. Consolidated Cash Flow Statement

Unit: RMB

Item	Accrual in the current period	Accrual in the last period
I. Cash flow generated from operating activities:		
Cash received from the sales of goods or rendering of services	1,512,516,483.16	1,636,352,953.22
Net increase of deposits from customers and other banks		
Net increase in borrowings from the central bank		
Net increase in borrowing funds from other financial institutions		
Cash received from the original insurance contract premium		
Net cash received from reinsurance premiums		
Net increase in policy holder deposits and investment funds		
Cash received from interests, fees and commissions		
Net increase in borrowing funds		

Net increase in repurchase business funds		
Net cash received from vicariously traded securities		
Refund of taxes and fees received	13,997,200.97	25,176,943.60
Other cash received related to operating activities	106,104,988.38	52,192,717.42
Subtotal of cash inflow from operating activities	1,632,618,672.51	1,713,722,614.24
Cash paid for purchase of goods or rendering of services	364,188,880.94	453,575,260.63
Net increase in customer loans and advances		
Net increase of deposits in central bank and other banks		
Cash paid for indemnity of original insurance contract		
Net increase in lending funds		
Cash received from interests, fees and commissions		
Cash paid for policy dividends		
Cash paid to and for employees	454,916,503.41	549,394,164.36
Various taxes and dues paid	155,102,070.14	261,391,946.90
Other cash paid related to operating activities	239,388,977.47	307,842,984.72
Subtotal of cash outflow from operating activities	1,213,596,431.96	1,572,204,356.61
Net cash flow from operating activities	419,022,240.55	141,518,257.63
II. Cash flow generated from investing activities:		
Cash received from withdrawing investment	236,838,107.31	162,587,386.56
Cash received from obtaining return on investment	8,663,634.81	2,613,039.56
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	114,556.06	20,649,106.20
Net cash received from disposal of subsidiaries and other business units	500,000.00	15,250,149.21
Other cash received related to investing activities	7,500,000.00	9,190,500.93
Subtotal of cash inflow from investing activities	253,616,298.18	210,290,182.46
Net cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets	131,546,206.61	144,125,931.38
Cash paid for investment	568,974,655.35	156,311,060.73
Net increase in pledged loans		
Net cash paid for disposal of subsidiaries and other business entity		20,000,000.00
Other cash received related to investing activities	17,142,857.00	169,870,093.99
Subtotal of cash outflow from investing activities	717,663,718.96	490,307,086.10

Net cash flow from investing activities	-464,047,420.78	-280,016,903.64
III. Cash flow generated from financing activities:		
Cash received from attracting investment	21,142,857.00	
Including: Cash received by subsidiaries from absorbing investments from minority shareholders	21,142,857.00	
Cash received from borrowings	833,025,301.32	634,086,899.50
Other cash received related to financing activities		12,590,667.92
Subtotal of cash inflow from financing activities	854,168,158.32	646,677,567.42
Cash paid for repaying debts	682,000,000.00	478,000,000.00
Cash paid for the distribution of dividends, profits or repayment of interests	51,814,597.34	38,686,008.93
Including: Dividends and profits paid to minority shareholders by subsidiaries	421,875.00	
Other cash received related to financing activities	38,190,778.84	182,053,706.15
Subtotal of cash outflow from financing activities	772,005,376.18	698,739,715.08
Net cash flow from financing activities	82,162,782.14	-52,062,147.66
IV. Effect of changes in exchange rate on cash and cash equivalents	1,333,632.32	1,664,154.20
V. Net increase in cash and cash equivalents	38,471,234.23	-188,896,639.47
Plus: Balance of cash and cash equivalents at the beginning of the period	3,614,387,490.21	4,099,954,989.87
VI. Balance of cash and cash equivalents at the end of the period	3,652,858,724.44	3,911,058,350.40

(II) Implementation of the adjustment of new accounting standards, and the financial statement related items at the beginning of the year for the first time from 2025

Applicable Not applicable

(III) Audit report

Whether the Q1 Report has passed the audit

Yes No

The Company's Q1 Report has not been audited.

Board of Directors of Lepu Medical Technology (Beijing) Co., Ltd.

Apr. 19, 2025